Develops cell therapies for cardiovascular and pulmonary diseases.
Dec 2025Revenue $0.00/yrExpenses $8.28M/yr
No trendCash runway ≈ 7 months from Jun 2026
Figures by year
When will BioCardia be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $8.28M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $8.28M | −$8.28M |
| Dec 2024 | $58.0K | $8.06M | −$8.00M |
| Dec 2023 | $477K | $12.1M | −$11.6M |
| Dec 2022 | $1.35M | $13.3M | −$11.9M |
| Dec 2021 | $1.01M | $13.6M | −$12.6M |
| Dec 2020 | $145K | $15.7M | −$15.5M |
| Dec 2019 | $710K | $14.9M | −$14.2M |
| Dec 2018 | $625K | $14.7M | −$14.1M |
| Dec 2017 | $479K | $12.9M | −$12.4M |
| Dec 2016 | $576K | $8.18M | −$7.61M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.